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Abstract
Objective: The aim of this study was to retrospectively analyze advanced 
oral tongue cancer to determine tumor characteristics, treatment patterns 
and any other prognostic factors that may influence the survival of patients 
with the disease.
Patients and Methods: The records of 70 patients with stage III to IVA oral 
tongue cancer (TNM system) seen between December 1999 and December 
2005 at one institution were reviewed. One group of patients had been 
treated with surgery plus adjuvant therapy (Group A), while the other group 
of patients had undergone definitive concurrent chemoradiotherapy (CCRT) 
without surgery (Group B). The chemotherapy protocol consisted of two 
month ly courses of cisplatin and fluorouracil as a concurrent regimen fol-
lowed by another 2-month course as an adjuvant systemic regimen. The regi-
men was cisplatin (20 mg/m2/d) on day 1 and fluorouracil (1000 mg/m2/d) 
on days 1 to 5.
Results: The 3-year overall survival, disease-free survival, local recurrence 
and distant metastasis rates in Groups A/B were 76%/18%, 75%/22%, 14%/
33% and 13%/27%, respectively. Significant differences were observed 
in the overall and disease-free survival in the two groups. Multivariate analy-
sis for predictors of overall survival across all patients, treatment types 
and local recurrence were significant. Furthermore, multivariate analysis to 
discover predictors of overall survival showed that a positive pathological 
finding for the margin or a margin < 1 mm in size, and extracapsular spread 
were significant.
Conclusion: Among the patients who were not candidates for surgery, the 
effect of definitive CCRT was not satisfactory. A higher dose of radiation was 
found to result in significantly better survival and local control in Group 
A. However, in Group B, while local control was better with higher doses, 
survival did not differ significantly. The effectiveness of radiotherapy might 
be increased with the use of brachytherapy, the use of more effective drugs 
such as a radiosensitizer or other recently introduced chemotherapy drugs. 
[Tzu Chi Med J 2009;21(1):52–58]
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1. Introduction
Oral tongue cancer is one of the more common intra-
oral malignancies. The spread of a tumor may occur 
by local invasion, through lymphatic involvement to 
regional lymph nodes or via the bloodstream to dis-
tant sites. Surgical excision has been the primary treat-
ment for early disease. However, the tumor may be 
deeply infiltrating or have an ill-defined edge, which 
makes it difficult to decide where the resection mar-
gin should be placed. Furthermore, lymphatic metas-
tases from oral tongue cancer are frequently seen and 
occur in between 15% and 80% of cases dependent 
on the stage [1,2]. Because of the difficulties of surgi-
cal excision and the high incidence of neck failure, 
most clinicians would agree that a multidisciplinary 
ap proach should produce optimal curative results and 
provide quality of life for a patient with advanced oral 
tongue cancer. Surgery with postoperative adjuvant 
radiotherapy is the standard treatment for advanced 
oral tongue cancer and this approach has a 5-year sur-
vival rate that varies between 30% and 50% [2–4]. 
The value of adding chemotherapy to definitive surgery 
and/or radiation when treating head and neck cancer 
has been extensively evaluated over the past 20 years. 
However, a survival advantage has been difficult to 
dem onstrate, particularly after neoadjuvant or sequen-
tial treatment. More recently, two large-scale random i-
zed trials by the Radiation Therapy Oncology Group 
(RTOG) and the European Organization for Research 
Treatment of Cancer (EORTC) have demonstrated the 
benefits of adjuvant concurrent chemoradiotherapy 
(CCRT) after radical surgery in high-risk head-and-neck 
cancer patients [5,6]; this infers that adjuvant CCRT 
should be used when there is extracapsular spread 
(ECS) and/or an unclear margin [7]. However, these two 
trials included head-and-neck tumors from all sites, 
which may have blurred the differences in survival at 
different sites. In addition, these two trials used differ-
ent inclusion criteria and had no subgroup analyses. 
The aim of this retrospective case analysis of advanced 
oral tongue cancers was to determine tumor character-
istics, treatment patterns or any other prognostic fac-
tors that influence disease survival.
2. Patients and methods
The records of 86 patients with stage III to IVA 
oral tongue cancer (TNM system) [8] seen between 
December 1999 and December 2005 in one institu-
tion were reviewed. Of these, 16 patients were ex-
cluded from the analysis because they were either 
treated with sur gery alone (10 patients), were lost to 
follow-up (4 pati ents) or had a synchronous second 
primary (2 pa tients); all were diagnosed histologically 
with oral tongue cancer by pathologists and none had 
a prior cancer. All patients were informed about their 
disease treatment, including potential benefits and 
pos sible side effects. One group of patients was treated 
with surgery plus adjuvant therapy (Group A), while 
the other group of patients had definitive CCRT with-
out surgery (Group B); the treatment regimen of the 
patients in the latter group was chosen for medical 
reasons (4 suffered from chronic liver disease, 2 suf-
fered from chronic lung dis ease, 2 had heart disease 
and the remainder refused surgery [14 patients]). All 
pa tients were treated by a multidisciplinary team group 
including a head and neck surgery team, radiation 
oncologists, medical on col ogists and dieticians.
2.1. Treatment
Surgery consisted of partial glossectomy, hemiglossec-
tomy or subtotal glossectomy with unilateral or bilat-
eral radical neck dissection. Pathology reports were 
reviewed for evidence of size, grade, type, surgical 
margins, lymph nodes involved, perineural invasion, 
vascular permeation, lymphatic permeation and ECS. 
Subclavian venous-access catheters were placed for 
nutritional support and administration of chemother-
apy. Adjuvant treatment was started 4–6 weeks after 
surgery.
Radiation therapy was delivered using the intensity-
modulated radiation technique (IMRT) via an inverse 
planning system (PLATO, Nucleotron Inc., Veenendaal, 
The Netherlands). The radiation field encompassed the 
primary tumor bed and neck lymph nodes. Treatment 
was delivered with a 6-MV multileaf collimator system 
(Precise, Elekta, Crawley, UK) using a step-and-shoot 
method with seven coplanar beams. Gross tumor vol-
ume (GTV) was defined as the gross disease as shown 
by imaging with the clinical target volume (CTV) de-
fined as GTV plus margin of 3–10 mm, depending on 
the proximity of critical structures. The critical normal 
structures used for optimization included the brain-
stem, spinal cord, parotid glands, optic nerves, chiasm, 
lenses, eyeballs, temporal lobes, temporomandibular 
joints, neck muscle, mastoid air cells and oral mucosa. 
Verification of the treatment plan and dose was car-
ried out before treatment; a weekly machine-check 
film involving electronic portal imaging was performed 
to ensure set-up accuracy during treatment. The pre-
scribed doses delivered by external beam radiotherapy 
were: 70–72 Gy to the GTV and positive neck nodes; 
60–66 Gy to the CTV together with 50–60 Gy to clini-
cally negative neck. For the adjuvant setting, these were 
60–72 Gy to GTV and positive neck nodes, 50–60 Gy 
to CTV and 50 Gy to pathologically negative neck. 
Doses were delivered at 1.8 Gy/day for 5 consecutive 
days by a linear accelerator with the patients lying 
supine wearing a mask. GTVs received a higher dose 
per fraction, which ranged from 1.8–2.16 Gy per day. 
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The dose delivered to the neck nodes was a dose per 
fraction ranging from 1.7–2.0 Gy per day. The spinal 
cord dose was limited to 45 Gy.
Chemotherapy was given as a definitive or adjuvant 
setting and is a regime routinely used in advanced oral 
cancer patients. The adjuvant setting was delivered 
4–6 weeks after surgery. Patients received radiother-
apy alone if they refused or were unfit for chemo-
therapy. The chemotherapy protocol consisted of two 
monthly courses of cisplatin and fluorouracil (5-FU) 
as a concurrent regimen followed by another 2-month 
course as an adjuvant systemic regimen. The regimen 
consisted of cisplatin (20 mg/m2/d) on day 1 and 5-FU 
(1000 mg/m2/d) on days 1–5. All consenting patients 
were eligible for chemotherapy if they met the follow-
ing criteria: ECOG performance status ≤ 2, serum 
creatinine level < 1.5 mg/dL, absolute neu tro phil count 
> 2000 cells/μL, platelet count > 10,000/μL. Toxicity 
was evaluated using the common toxicity criteria of 
the National Cancer Institute [9]. Cisplatin and 5-FU 
were withheld if the absolute neutrophil count dropped 
below 1500 cells/μL or the platelet count dro pped 
below 75,000 cells/μL. For grades 3 and 4 renal tox-
icity, cisplatin was withheld until the patient’s creati-
nine level was < 1.5 mg/dL. Cisplatin and 5-FU were 
administered at 70% of the initial dose thereafter. 
Ra dio therapy was withheld only if the neutrophil count 
dropped below 1000 cells/μL or the platelet count 
drop ped below 50,000 cells/μL.
2.2. Patient follow-up and patterns of 
failure
Patients were assessed at 3, 6 and 12 months and 
then every 6–12 months for 5 years, or more often if 
clinically indicated. Survival was calculated from the 
date of diagnosis to the most recent follow-up or date 
of recurrence or death. Treatment responses to CCRT 
were defined according to the response evaluation 
cri teria in solid tumors (RECIST) and classified as com-
plete response, partial response, progressive disease 
or stable disease [10]. Briefly, complete response was 
defined as an absence of carcinoma on biopsy or the 
disappearance of radiographic evidence of the disease. 
Partial response was defined as a reduction of at least 
30% in the size of the tumor as assessed by radiog-
raphy. Progressive disease was defined increase in 
the size of the tumor by at least 20%. Stable disease 
was defined as neither sufficient shrinkage to qualify 
for a partial response nor a sufficient increase to 
qualify for progressive disease. The pattern of failure 
for both groups was defined according to the first site 
of failure. Local failure was defined as recurrence of 
the primary tumor or metastasis to the regional lymph 
nodes. Dis tant failure was defined as metastasis to any 
site beyond the primary tumor and to the regional 
lymph nodes. After recurrence or metastasis, pa-
tients were given salvage therapy as determined by 
their physicians.
2.3. Statistical analysis
The baseline characteristics of the two groups were 
compared using a t test for the continuous variables 
and a χ2 test for the categorical variables. The Kaplan-
Meier method was used for the survival analysis [11]. 
The difference between the survival curves was de-
termined using the log-rank test [12]. Multivariate 
analysis to identify significant prognostic factors was 
done using Cox’s regression model. Covariates were 
selected in a forward fashion using their maximum 
likelihood ratio. A matched-pair analysis was used to 
compare radiotherapy doses. The matching variables 
were performance, T status, N status and stage. SPSS 
version 12.0 (SPSS Inc., Chicago, IL, USA) was used for 
the analysis of all data. A statistical significant differ-
ence was defined by a p value of less than 0.05.
3. Results
Seventy patients were evaluated. There were 48 were 
in Group A and 22 were in Group B. There was no sig-
nificant difference in the T and N staging between the 
two groups (Table 1). The most frequent symptom at 
diagnosis, present in over 90% of individuals, was an 
ulcer, an exophytic mass or a neck mass. Other com-
mon symptoms included bleeding, speech difficulties 
or pain. The patient characteristics are presented in 
Table 2.
3.1. Treatment outcome
Median patient follow-up at the commencement of 
the analysis was 18 months (range, 5–63 months). 
Among the patients in Group A, 21 patients received 
adjuvant radiation alone while the others received 
adjuvant CCRT. The patients received 3960–7020 cGy 
of radiation (median, 6120 cGy). Forty of the 48 pa-
tients received the full planned dose of radiation and 
Table 1 — Tumor (T) and nodal (N) staging
 Group A Group B
 T1 T2 T3 T4A   T1 T2 T3 T4A
N0   4 16 20 N0   1 5 6
N1 1 7 4 6 18 N1 0 4 2 4 10
N2 0 2 3 5 10 N2 0 1 2 3 6
 1 9 11 27   0 5 5 12
There was no significant difference in T and N stages between the 
two treatment groups.
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eight had incomplete radiation because of treatment-
induced com plications. Thirteen of the 27 patients 
who received adjuvant CCRT completed the full course 
of monthly chemotherapy; the others received less 
than four cycles at a reduced dose. The median sur-
vival for Group A was 23 months (range, 7–63 months). 
The estimated 3-year overall survival was 76%. The 
3-year disease-free survival, local recurrence and 
distant metastasis rates were 75%, 14% and 13%, 
res pec tively. The 22 patients in Group B received 
5220–7200 cGy of radiation (median, 7020 cGy). Of 
these 22 patients, 11 completed the full course of 
monthly chemotherapy, while the others received fewer 
than four cycles at a reduced dose. The full planned 
dose of radiation was given to 16 patients in the CCRT 
group and six pa tients did not complete course be-
cause of treatment-induced complications. Of the 16 
patients who completed definitive CCRT, 10 achieved 
a complete response; three a partial response; two 
showed stable disease and one showed progressive 
disease when assessed at the 3-month follow-up. 
Eight patients developed recurrence and/or metasta-
sis after follow-up (Table 3). The median survival was 
18 months (range, 6–58 months), with an estimated 
3-year overall survival of 18%. The 3-year disease-free 
survival, local recurrence and distant metastasis rate 
were 22%, 33% and 27%, respectively. In addition, if 
we excluded the suboptimal dose patients from analy-
sis, the 3-year overall, disease-free survival, local recur-
rence and distant metastasis rates were 38%, 42%, 
26% and 22%, respectively.
Significant differences were observed in the over-
all and disease-free survival between the two groups 
(p < 0.05; Fig. 1). Marginal significance was also ob-
served when local control (p = 0.07) and distant 
metastasis-free rate (p = 0.06) were assessed in the 
two groups. Furthermore, significant differences were 
also observed in the overall and disease-free survival 
between the two groups (p < 0.05) if we excluded the 
suboptimal dose Group B patients from the analysis. 
Using multivariate analysis for the predictors of over-
all survival with all patients, only treatment type and 
local recurrence were significant (Table 4). However, 
multivariate analysis for the predictors of overall sur-
vival showed that a positive pathological examina-
tion for the margin, a margin < 1 mm and ECS were 
significant in Group A (Table 5).
3.2. Radiotherapy dose
There was no significant difference in performance, 
T status, N status and stage between the two groups. 
Table 2 — Patient characteristics*
 Group A Group B
Sex
   All 48 22
   Male 41 (85) 20 (91)
   Female 7 (15) 2 (9)
Age (yr)
   Median 48 51
   Range 27–77 45–79
Histological differentiation
   Well 3 (7) 2 (9)
   Moderate 37 (77) 16 (73)
   Poor 4 (8) 2 (9)
   Missing 4 (8) 2 (9)
Performance status (ECOG)
   0 21 (44) 7 (32)
   1 17 (35) 10 (45)
   2 10 (21) 5 (23)
AJCC 1997 stage group
   3 16 (33) 7 (32)
   4 32 (67) 15 (68)
*Data presented as n (%). ECOG = Eastern Cooperative Oncology 
Group; AJCC = American Joint Committee on Cancer.
Table 3 — Site of recurrence in oral tongue cancer
Site of recurrence
 Group A Group B
 patients (n) patients (n)
Local 1 3
Regional 2 1
Distant 1 2
Local and regional 0 1
Local and distant 0 0
Regional and distant 1 1
All three sites 0 1
0 10 20 30 40 50 60 70
Follow-up (mo)
0.0
0.2
0.4
0.6
0.8
1.0
O
ve
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ll 
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al
Group A
Group B
Fig. 1 — Kaplan-Meier survival curves for overall survival 
for two different treatment modalities.
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Nonetheless, a higher dose of radiation resulted in 
significantly better survival and local control in Group 
A (p < 0.05), with a total dose of > 65 Gy yielding both 
better local control at 3 years (95% vs. 67%; p < 0.05) 
and better 3-year survival (88% vs. 61%; p < 0.05) 
than treatment with < 65 Gy. In Group B, 3-year local 
control in patients receiving > 70 Gy was better than 
in those receiving < 70 Gy (50% vs. 16%) but survival 
did not differ significantly.
4. Discussion
In the present study, locoregional recurrence and 
treatment with definitive CCRT were found to be ad-
verse prognostic factors in the multivariate analysis. 
It is generally considered that surgery and radiother-
apy are equivalent when treating early disease. How-
ever, with advanced deeply infiltrative lesions the best 
management is considered to be a primary surgical 
approach with postoperative therapy. When radiother-
apy alone was used for T1 and T2 tumors, 5-year sur-
vival rates of 61% and 74%, respectively, could be 
achieved, but the results for larger tumors were poor 
[13]. In addition, Kramer et al reported that the over-
all survival was significantly better in stage II patients 
who received combined therapy compared with ra-
diotherapy alone (73% vs. 30%) [14]. In another study 
by Aksu et al, the 5-year overall survival, the relapse-
free survival and the disease-specific survival rates 
were all significantly better in the surgery plus post-
operative radiotherapy group than in the radiotherapy 
alone group, and this was true for all stage patients 
[4]. Even with combined chemotherapy and definitive 
radiation, the estimated 5-year survival rates range 
from 50% to 70% for stages I and II and from 15% to 
30% for stages III and IV [14,15]. In this study, when 
we evaluated the whole group or excluded the sub-
optimal dose patients from analysis, the overall sur-
vival and disease-free survival were all significantly 
better in Group A than in Group B. In advanced pa-
tients who are not candidates for surgery, the effect 
of definitive CCRT was not satisfactory.
Surgery with postoperative adjuvant radiotherapy 
is the standard treatment for patients with advanced 
oral tongue cancer, and the 5-year survival reportedly 
varies between 30% and 50% [2–4]. From recent stud-
ies, adjuvant CCRT is indicated in ECS and/or when 
there are unclear margins [5–7]. With surgery, an ade-
quate margin would seem to be crucial to local con-
trol because of the high rate of occult disease (41%). 
Local recurrence was observed in 15% of patients 
Table 4 — Factors associated with overall survival
 3-yr survival rate (%) Univariate analysis (p) Multivariate analysis (p)
Treatment type
   Group A 76 < 0.001* 0.009*
   Group B 18  HR = 0.11 (95% CI, 0.02–0.57)
Locoregional recurrence  < 0.001* < 0.001*
   Present 10  HR = 9.88 (95% CI, 3.2–26.8)
   Absent 82
Age (yr)
   < 45 92 0.02* Not significant
   ≥ 45 50
Tumor size
   < 4 cm 80 0.02* Not significant
   ≥ 4 cm 44
Stage
   III 66 0.02* Not significant
   IV 31
T stage
   T3 76 0.05* Not significant
   T4 62
Nodal status
   Positive 52 0.04* Not significant
   Negative 80
*Statistically significant difference. HR = hazard ratio; CI = confidence interval.
Table 5 — Multivariate regression analysis of histological 
findings
Variable p
Positive or margin < 1 mm 0.032
Extracapsular spread 0.046
Perineural invasion 0.164
Two or more lymph nodes involved 0.126
Vascular permeation 0.586
Grade 0.968
Size 0.984
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with close margins (< 1 cm) and in 9% of patients with 
adequate margins (> 1 cm) [16]. In another study of 
oral tongue cancer treated with surgery alone, it was 
found that a distance of > 5 mm from the resection 
margin was a significant prognostic factor for both 
local control and survival [17]. ECS is also another 
important significant factor. The extent of ECS on 
histopa thological review of the involved lymph nodes 
was measured from the capsular margin to the farthest 
perinodal extension in mm. As the ECS increased, the 
recurrence rate increased in oral tongue cancer from 
20.4% to 83.8%, respectively [18]. ECS was also sig-
nificantly associated with higher rates of locoregional 
recurrence, distant metastasis and decreased survival 
in oral tongue cancer patients. The 5-year disease-
specific and overall survival rates for pN0 patients 
were 88% and 75%; for pN+/ECS− patients were 65% 
and 50%; and for pN+/ECS+ patients were 48% and 
30%, respectively. The patterns of failure for the pN0, 
pN+/ECS− and, pN+/ECS+ groups showed overall re-
currence rates of 19.8%, 34.2% and 51.1%, respec-
tively. The regional failure rates were 11.5%, 19.2% and 
28.9%, respectively. Furthermore, the distant me tas-
tases rates were 3.3%, 8.2% and 24.4%, respectively 
[19]. However, adjuvant CCRT, as opposed to adjuvant 
radiotherapy alone, appeared to benefit patients with 
ECS [2]. The present study produced similar results 
and the significant factors affecting survival in Group 
A were positive pathological finding for the margin or 
a margin < 1 mm and extracapsular spread.
Different radiation doses have also been shown to 
be associated with differences in tumor control. One 
randomized trial study reported a dose of < 57.6 Gy 
was associated with a higher risk of recurrence. Doses 
> 63 Gy did benefit patients with ECS [20]. Further-
more, a close surgical margin requires high doses, 
such as 70 Gy, because of the difficulty in eradicating 
the tumor [21]. In our study, a higher dose of radia-
tion in Group A resulted in significantly better survival, 
together with better local control. This differed from 
Group B in which a higher dose was only associated 
with better local control.
Toxicity is often a concern in combined chemo-
therapy, and a recent study showed a 74% incidence 
of moderate-to-severe acute toxicity when using a com-
bined modality treatment [22]; another study found 
that CCRT-treated patients had a higher incidence of 
acute grade 3 and acute grade 4 toxicity compared 
with those treated with radiation alone (71% vs. 39%) 
[23]. In the present study, nearly half of our patients 
had severe toxicity during therapy that required treat-
ment modification. More effective and safer drugs such 
as radiosensitizers or modern chemotherapy drugs 
should be considered when carrying out a multimodal 
treatment strategy.
Because this is a retrospective study, a number of 
fac tors in terms of patients and tumor characteristics 
could not be controlled and may have biased the re-
sults. However, when we consider the advanced pa-
tients who were not candidates for surgery, the effect 
of definitive CCRT was not satisfactory. Another impor-
tant finding was that a higher dose of radiation re-
sulted in a significantly better survival and improved 
local control. Thus, it may be possible to increase the 
effectiveness of radiotherapy by the use of brachy-
therapy or more effective drugs.
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